Effect of High-Intensity Focused Electromagnetic (HIFEM) Technology in the Treatment of SUI in Chinese Men Undergone Robotic Radical Prostatectomy
Launched by CHINESE UNIVERSITY OF HONG KONG · Sep 6, 2024
Trial Information
Current as of June 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment method called High-Intensity Focused Electromagnetic (HIFEM) Technology to help men who have urinary incontinence, specifically after having robotic radical prostatectomy surgery. The trial aims to see how effective and safe this new technology is compared to the usual care that patients receive for this condition. It is currently recruiting male participants who are at least 54 years old and have undergone the surgery.
To be eligible for the study, participants must be able to complete a simple 1-hour test that measures urine loss, and they need to agree to participate by signing a consent form. However, men with certain conditions, like a history of urinary incontinence before surgery, active urinary tract infections, or those with specific medical devices or medications that could interfere with the treatment, cannot join. If you participate, you can expect to receive either the HIFEM treatment or standard care, and the study will monitor your progress to determine the benefits of the new technology.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Undergone robotic radical prostatectomy
- • Able to carry out 1-hour pad test
- • Voluntary participation and signing of the informed consent form
- Exclusion Criteria:
- • Pre-existing stress urinary incontinence
- • Post-void residual urine greater than 200ml
- • Active urinary tract infection
- • Urethral or bladder fistula
- • History of pelvic irradiation
- • Neurological condition (Spinal cord problems, stroke with poor neurological recovery, epilepsy, Parkinson disease, multiple sclerosis)
- • Previous surgery for SUI
- • Concurrent medication with diuretics, serotonin-norepinephrine reuptake inhibitors or any other medication known to worsen incontinence
- • Condition contraindicated for electromagnetic therapy i.e. Arrhythmia, on a pacemaker or implanted metallic device; Coagulopathy or on anticoagulant
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, , Hong Kong
Patients applied
Trial Officials
Chi Fai NG, MD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported